> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Again Cites Catalent Facility
- URL: https://www.fdaweb.com/fda-again-cites-catalent-facility/
- Published: 2024-02-06T12:00:00.000Z
- Updated: 2026-09-14T14:22:12.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5156306

A Bloomington, IN, Catalent facility that is being used by Novo Nordisk to expand production of its popular weight-loss drug Wegovy (semaglutide) is not meeting FDA safety and quality requirements. Bloomberg News [reports](%28Bloomberg%29%20--%20One%20of%20the%20Catalent%20Inc.%20factories%20Novo%20Nordisk%20A/S%20is%20buying%20to%20boost%20supply%20of%20its%20popular%20weight-loss%20injection%20Wegovy%20isn’t%20meeting%20safety%20and%20quality%20standards,%20according%20to%20an%20inspection%20document.) that it obtained an FDA report on its 10/2023 and 11/2023 inspection at the plant through a Freedom of Information Act request.

The news service says the report documented multiple instances of workers failing to ensure the quality and purity of drugs produced at the plant. Bloomberg also says it was reported that a “pest” had been found on a manufacturing line handling syringes.

The report says Novo Nordisk has agreed to pay $11 billion for the Indiana facility and two others as part of its expansion plan for Wegovy.

Bloomberg says the Indiana plant was in the news in recent years over shortcomings that led to a tightened supply of Moderna’s Covid-19 vaccine and problems that affected a Regeneron application for a stronger version of its Eylea optical medicine.